Plain-English translation of NCT04121468 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a medication commonly used to treat diabetes, might help repair nerve damage in young people with multiple sclerosis (MS). Researchers believe the medication may stimulate the brain's natural ability to heal damaged nerve fibers. The study will follow participants over one year to see if the treatment is safe and whether it shows promise for helping the nervous system recover.
Multiple sclerosis damages the protective coating around nerve fibers, especially in the eyes and brain, and currently available treatments mainly prevent new damage rather than repair old damage. This trial explores whether this medication might work differently—by helping the body's own repair systems rebuild damaged nerves—opening a potential new approach to MS treatment.
You likely qualify if…
You likely don't qualify if…
You would join the study for 12 months total. You'll be randomly assigned to start taking the medication at one of three different time points (month 3, 6, or 9), meaning you'll take a placebo (dummy pill) first, then switch to the active medication for at least 3 months. The medication starts at a low dose and increases gradually if you tolerate it well, with a maximum dose of 2,000 mg per day taken in divided doses. You'll have regular check-ins to monitor for side effects and to have eye tests and other assessments to see if the treatment is helping.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Canada